STOK
Stoke Therapeutics Inc

1,010
Mkt Cap
$2.01B
Volume
702,743.00
52W High
$38.69
52W Low
$5.35
PE Ratio
53.37
STOK Fundamentals
Price
$35.28
Prev Close
$35.22
Open
$36.15
50D MA
$30.04
Beta
1.28
Avg. Volume
872,643.36
EPS (Annual)
-$1.65
P/B
6.30
Rev/Employee
$285,585.94
Loading...
Loading...
News
all
press releases
Stoke Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine and has a lead investigational...
Business Wire·1d ago
News Placeholder
More News
News Placeholder
Stoke Therapeutics (NASDAQ:STOK) Price Target Raised to $35.00 at Chardan Capital
Chardan Capital lifted their price target on shares of Stoke Therapeutics from $24.00 to $35.00 and gave the company a "buy" rating in a report on Monday...
MarketBeat·2d ago
News Placeholder
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of "Buy" by Analysts
Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) has earned a consensus rating of "Buy" from the ten analysts that are presently covering the company, MarketBeat reports. Two investment...
MarketBeat·17d ago
News Placeholder
Corient Private Wealth LLC Invests $7.49 Million in Stoke Therapeutics, Inc. $STOK
Corient Private Wealth LLC purchased a new stake in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC...
MarketBeat·19d ago
News Placeholder
Assenagon Asset Management S.A. Has $21.16 Million Position in Stoke Therapeutics, Inc. $STOK
Assenagon Asset Management S.A. raised its holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 67.3% in the third quarter, according to its most recent Form 13F filing with the...
MarketBeat·19d ago
News Placeholder
Equities Analysts Set Expectations for STOK FY2027 Earnings
Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - HC Wainwright boosted their FY2027 earnings per share (EPS) estimates for Stoke Therapeutics in a report issued on Monday, December 15th. HC...
MarketBeat·21d ago
News Placeholder
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine and has a lead investigational...
Business Wire·22d ago
News Placeholder
Redmile Group LLC Cuts Stock Holdings in Stoke Therapeutics, Inc. $STOK
Redmile Group LLC lessened its position in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 2.5% in the second quarter, according to the company in its most recent 13F filing with...
MarketBeat·26d ago
News Placeholder
Stoke Therapeutics (NASDAQ:STOK) General Counsel Jonathan Allan Sells 3,978 Shares of Stock
Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) General Counsel Jonathan Allan sold 3,978 shares of the stock in a transaction that occurred on Monday, December 8th. The shares were sold at...
MarketBeat·27d ago
News Placeholder
Stoke Therapeutics (NASDAQ:STOK) Director Sells $433,386.10 in Stock
Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) Director Edward Md Kaye sold 13,430 shares of Stoke Therapeutics stock in a transaction on Monday, December 8th. The shares were sold at an...
MarketBeat·27d ago
<
1
2
...
>

Latest STOK News

View

Advertisement|Remove ads.

Advertisement|Remove ads.